EcoDrugPlus

Protein Kinase C, Zeta

Ensembl ID : ENSORLG00000016850
Gene Symbol: PRKCZ
4 Cross references
201 Possible Orthologues:

Protein Kinase D1

Ensembl ID : ENSORLG00000010716
Gene Symbol: PRKD1
3 Cross references
204 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSORLG00000017403
Gene Symbol: PRKD3
4 Cross references
209 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSORLG00000005452
Gene Symbol: PRKDC
4 Cross references
184 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSORLG00000008993
Gene Symbol: PTK2BB
4 Cross references
195 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSORLG00000000470
Gene Symbol: PTPN11A
4 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSORLG00000017385
Gene Symbol: PTPRB
4 Cross references
189 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine

Ensembl ID : ENSORLG00000019788
Gene Symbol: LOC101155172
3 Cross references
197 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSORLG00000023591
Gene Symbol: LOC101167634
4 Cross references
263 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSORLG00000003515
Gene Symbol: P2RX3A
4 Cross references
192 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSORLG00000028530
Gene Symbol: P2RX3B
4 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSORLG00000005881
Gene Symbol: P2RY1
4 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).